HK1077582A1 - Aryl 5-thio beta-d-glucopyranside derivatives and remedies for diabetes containing sthe same - Google Patents

Aryl 5-thio beta-d-glucopyranside derivatives and remedies for diabetes containing sthe same

Info

Publication number
HK1077582A1
HK1077582A1 HK05109578A HK05109578A HK1077582A1 HK 1077582 A1 HK1077582 A1 HK 1077582A1 HK 05109578 A HK05109578 A HK 05109578A HK 05109578 A HK05109578 A HK 05109578A HK 1077582 A1 HK1077582 A1 HK 1077582A1
Authority
HK
Hong Kong
Prior art keywords
glucopyranside
remedies
aryl
derivatives
diabetes containing
Prior art date
Application number
HK05109578A
Other languages
English (en)
Inventor
Masakazu Sato
Hiroyuki Kakinuma
Hajime Asanuma
Original Assignee
Taiso Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiso Pharmaceutical Co Ltd filed Critical Taiso Pharmaceutical Co Ltd
Publication of HK1077582A1 publication Critical patent/HK1077582A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
HK05109578A 2002-08-09 2005-10-27 Aryl 5-thio beta-d-glucopyranside derivatives and remedies for diabetes containing sthe same HK1077582A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002233015 2002-08-09
JP2003097839 2003-04-01

Publications (1)

Publication Number Publication Date
HK1077582A1 true HK1077582A1 (en) 2006-02-17

Family

ID=31719867

Family Applications (2)

Application Number Title Priority Date Filing Date
HK05109578A HK1077582A1 (en) 2002-08-09 2005-10-27 Aryl 5-thio beta-d-glucopyranside derivatives and remedies for diabetes containing sthe same
HK05111661A HK1079532A1 (en) 2002-08-09 2005-12-17 Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK05111661A HK1079532A1 (en) 2002-08-09 2005-12-17 Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides

Country Status (19)

Country Link
US (2) US7414072B2 (fr)
EP (2) EP1528066A4 (fr)
JP (2) JPWO2004014930A1 (fr)
KR (2) KR100588457B1 (fr)
CN (2) CN100341885C (fr)
AU (2) AU2003254903B9 (fr)
BR (1) BR0310006A (fr)
CA (2) CA2478889A1 (fr)
HK (2) HK1077582A1 (fr)
HR (1) HRP20040814A2 (fr)
MX (2) MXPA04009265A (fr)
NO (2) NO20043733L (fr)
NZ (1) NZ535229A (fr)
PL (2) PL372865A1 (fr)
RU (1) RU2322449C2 (fr)
TW (2) TWI274055B (fr)
UA (1) UA77300C2 (fr)
WO (2) WO2004014931A1 (fr)
ZA (1) ZA200407187B (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
WO2004043471A1 (fr) * 2002-11-13 2004-05-27 Taisho Pharmaceutical Co., Ltd. Medicament antipruritique
JPWO2004089966A1 (ja) * 2003-04-01 2006-07-06 大正製薬株式会社 選択的なヘテロアリール５−チオ−β−Ｄ−アルドヘキソピラノシドの製造法
MXPA06001274A (es) 2003-08-01 2006-04-11 Tanabe Seiyaku Co Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
ZA200700755B (en) * 2004-07-26 2009-05-27 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
JP5073948B2 (ja) * 2005-01-31 2012-11-14 田辺三菱製薬株式会社 医薬組成物
MY147375A (en) 2005-01-31 2012-11-30 Mitsubishi Tanabe Pharma Corp Indole derivatives
JP2009167104A (ja) * 2006-05-02 2009-07-30 Taisho Pharmaceutical Co Ltd フェニル５−チオグリコシド化合物
EP1854806A1 (fr) * 2006-05-02 2007-11-14 MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thioglycosides en tant que composés pharmaceutiques
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007140191A2 (fr) 2006-05-23 2007-12-06 Theracos, Inc. Inhibiteurs de transport de glucose et procédés d'utilisation
KR20090023570A (ko) 2006-06-29 2009-03-05 다이쇼 세이야꾸 가부시끼가이샤 Ｃ-페닐 1-티오글루시톨 화합물
TWI418556B (zh) 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
FR2906247B1 (fr) * 2006-09-27 2008-12-26 Fournier S A Sa Lab Nouveaux derives de 5-thioxylopyranose
TWI499414B (zh) * 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
EP2072522A4 (fr) 2006-10-13 2010-01-06 Chugai Pharmaceutical Co Ltd Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
WO2008070609A1 (fr) 2006-12-04 2008-06-12 Janssen Pharmaceutica N.V. Dérivés de glycopyranosyle contenant du thiényle en tant qu'antidiabétiques
CN101611023A (zh) 2006-12-14 2009-12-23 大正制药株式会社 1－苯基1－硫代－d－山梨醇衍生物
US7795228B2 (en) * 2006-12-28 2010-09-14 Theracos, Inc. Spiroheterocyclic glycosides and methods of use
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
JP5583003B2 (ja) 2007-04-02 2014-09-03 セラコス・インコーポレイテッド ベンジルグルコシド誘導体およびその用途
AU2008279424B2 (en) 2007-07-26 2013-06-13 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
KR101107425B1 (ko) * 2007-08-23 2012-01-19 테라코스, 인코포레이티드 벤질벤젠 유도체 및 사용 방법
DK2200606T3 (en) 2007-09-10 2017-12-04 Janssen Pharmaceutica Nv PROCEDURE FOR THE PREPARATION OF RELATIONSHIP USED AS INHIBITORS OF SGLT
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
CA2730734C (fr) 2008-07-15 2017-04-25 Theracos, Inc. Composes de 2,3,4-trihydroxy-tetrahydropyranyl-benzylbenzene deuterates presentant une activite inhibitrice de cotransporteur sodium-glucose
CA2935838C (fr) * 2008-08-22 2018-04-17 Theracos Sub, Llc Procedes de preparation d'inhibiteurs de sglt2
EP2334687B9 (fr) * 2008-08-28 2012-08-08 Pfizer Inc. Dérivés de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
PT2451797E (pt) 2009-07-10 2013-06-25 Janssen Pharmaceutica Nv Processo de cristalização para o 1-(β-d-glucopiranosilo)-4-metilo-3-[5-(4-fluorofenilo)-2-tienilometilo]benzeno
ME02634B (fr) 2009-10-14 2017-06-20 Janssen Pharmaceutica Nv Procédé de préparation de composés utiles comme inhibiteurs de sglt2
PT2496583E (pt) 2009-11-02 2015-01-14 Pfizer Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
TWI599360B (zh) 2010-05-11 2017-09-21 健生藥品公司 醫藥調配物
WO2011153712A1 (fr) 2010-06-12 2011-12-15 Theracos, Inc. Forme cristalline d'inhibiteur de sglt2 de type benzyl-benzène
ME02469B (fr) 2011-04-13 2017-02-20 Janssen Pharmaceutica Nv Procédé de préparation de composés utiles en tant qu'inhibiteurs de sglt2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
KR20170082650A (ko) 2012-03-28 2017-07-14 후지필름 가부시키가이샤 1-(2-디옥시-2-플루오로-4-티오-β-D-아라비노푸라노실)시토신의 염
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
KR20170001722A (ko) 2012-08-13 2017-01-04 후지필름 가부시키가이샤 1-(2-데옥시-2-플루오로-4-티오-β-D-아라비노푸라노실)시토신의 합성 중간체, 티오뉴클레오시드의 합성 중간체, 및 그들의 제조법
CA2905993C (fr) 2013-03-14 2022-12-06 Tolero Pharmaceuticals, Inc. Derives de 4-amino-pyrimidinyle-2-amino-phenyle substitues et compositions pharmaceutiques a base de ceux-ci en tant qu'inhibiteurs dejak2 et d'alk2
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP4000608A1 (fr) 2013-04-18 2022-05-25 Boehringer Ingelheim International GmbH Composition pharmaceutique, procédés de traitement et leurs utilisations
CN105611920B (zh) 2013-10-12 2021-07-16 泰拉科斯萨普有限责任公司 羟基-二苯甲烷衍生物的制备
EP3109245B1 (fr) 2014-02-18 2018-01-03 FUJIFILM Corporation Composé de sucre type squelette de thiolane et procédé de fabrication de celui-ci
JP6204223B2 (ja) * 2014-02-19 2017-09-27 富士フイルム株式会社 チオピラノース化合物等の製造方法
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
WO2018043530A1 (fr) 2016-08-31 2018-03-08 富士フイルム株式会社 Agent antitumoral, activateur d'effet antitumoral et kit anti-tumoral
CA3089728C (fr) 2018-01-29 2023-01-10 Fujifilm Corporation Agent antitumoral contre le cancer biliaire et methode de traitement du cancer biliaire
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3055135B2 (ja) * 1996-12-26 2000-06-26 田辺製薬株式会社 プロピオフェノン誘導体及びその製法
ES2176600T3 (es) 1996-12-26 2002-12-01 Tanabe Seiyaku Co Derivado de la propiofenona y procedimientos para su preparacion.
UA71994C2 (en) 1999-08-31 2005-01-17 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivatives, a pharmaceutical composition containing these derivatives and intermediate compounds for the preparation thereof
FR2801055B1 (fr) * 1999-11-17 2002-02-08 Fournier Ind & Sante Derives de beta-d-5-thioxylose, procede de preparation et utilisation en therapeutique
WO2001068660A1 (fr) * 2000-03-17 2001-09-20 Kissei Pharmaceutical Co., Ltd. Derives glucopyranosyloxybenzylbenzene, preparations medicinales les contenant et intermediaires pour la preparation desdits derives
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
EP1272584B1 (fr) 2000-05-20 2004-03-10 Tesa AG Utilisation d'un support papier a haute densite comme bande support dans un materiau de recouvrement pour un ruban adhesif
PL205607B1 (pl) * 2000-09-29 2010-05-31 Kissei Pharmaceutical Pochodna glukopiranozyloksybenzylobenzenu, kompozycja farmaceutyczna zawierająca tą pochodną oraz zastosowanie tej pochodnej do wytwarzania kompozycji farmaceutycznej
EP1338603B1 (fr) 2000-11-02 2010-01-20 Ajinomoto Co., Inc. Nouveaux derives du pyrazole et remedes au diabete contenant ces derniers
CZ305971B6 (cs) 2000-12-28 2016-06-01 Kissei Pharmaceutical Co., Ltd. Deriváty glukopyranosyloxypyrazolu a jejich použití v léčivech
US7271153B2 (en) 2001-06-20 2007-09-18 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor
CN1761676A (zh) * 2003-04-01 2006-04-19 大正制药株式会社 杂芳基5－硫代－β－D－吡喃葡糖苷衍生物及含有该衍生物的糖尿病治疗药
JPWO2004089966A1 (ja) 2003-04-01 2006-07-06 大正製薬株式会社 選択的なヘテロアリール５−チオ−β−Ｄ−アルドヘキソピラノシドの製造法

Also Published As

Publication number Publication date
ZA200407187B (en) 2006-02-22
PL372865A1 (en) 2005-08-08
JP3813160B2 (ja) 2006-08-23
CN1312165C (zh) 2007-04-25
KR100588457B1 (ko) 2006-06-12
RU2322449C2 (ru) 2008-04-20
CA2493491A1 (fr) 2004-02-19
MXPA04009265A (es) 2005-01-25
UA77300C2 (en) 2006-11-15
TW200409778A (en) 2004-06-16
BR0310006A (pt) 2005-02-15
WO2004014931A1 (fr) 2004-02-19
HK1079532A1 (en) 2006-04-07
TWI274055B (en) 2007-02-21
AU2003254903B2 (en) 2008-07-31
JPWO2004014930A1 (ja) 2005-12-02
HRP20040814A2 (en) 2005-06-30
US20050256317A1 (en) 2005-11-17
JPWO2004014931A1 (ja) 2005-12-02
AU2003254903A1 (en) 2004-02-25
MXPA05000725A (es) 2005-04-08
CN1675233A (zh) 2005-09-28
US20050209309A1 (en) 2005-09-22
NO20050650L (no) 2005-03-04
CN100341885C (zh) 2007-10-10
KR20050056194A (ko) 2005-06-14
TW200406396A (en) 2004-05-01
NO20043733L (no) 2004-10-20
EP1528066A4 (fr) 2007-05-02
WO2004014930A1 (fr) 2004-02-19
KR20050018642A (ko) 2005-02-23
CN1639180A (zh) 2005-07-13
EP1541578A1 (fr) 2005-06-15
RU2004135914A (ru) 2005-05-10
AU2003254904A1 (en) 2004-02-25
US7414072B2 (en) 2008-08-19
PL375298A1 (en) 2005-11-28
US7250522B2 (en) 2007-07-31
AU2003254903B9 (en) 2008-08-21
NZ535229A (en) 2006-05-26
CA2478889A1 (fr) 2004-02-19
EP1528066A1 (fr) 2005-05-04

Similar Documents

Publication Publication Date Title
HK1077582A1 (en) Aryl 5-thio beta-d-glucopyranside derivatives and remedies for diabetes containing sthe same
PL377656A1 (pl) Ligandy Ó2Ű do różnych zastosowań farmaceutycznych
IL162548A0 (en) 4-Oxoquinoline derivatives and pharmaceutical compositions containing the same
EP1609799A4 (fr) Derives heteroaryle 5-thio-beta-d-glucopyranoside et medicaments contre le diabete contenant ces derives
IL166482A0 (en) Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same
IL178297A0 (en) Hydrazide derivatives and pharmaceutical compositions containing the same
HK1082249A1 (en) Isoquinoline derivatives having kinasae inhibitoryactivity and drugs containing the same
IL173602A0 (en) Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same
IL173627A0 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
IL173051A0 (en) N-glucoside derivatives and pharmaceutical compositions containing the same
IL164209A0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
IL166620A0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
IL171997A0 (en) Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same
IL175214A0 (en) 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same
IL164798A0 (en) Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
PL377791A1 (pl) Pochodne 3-aminopiperydyny i sposoby ich wytwarzania
IL172159A0 (en) 2-oxo-pyridine derivatives and pharmaceutical compositions containing the same
AU2003291024A1 (en) Rhodanine derivatives and pharmaceutical compositions containing them
PL359321A1 (en) New salt perindopryl and pharmaceutical composunds containing it
AU2003234929A1 (en) Therapeutic agent for diabetes
AU2003205558A1 (en) Thioibotenic acid and derivatives thereof
AU2003208673A1 (en) Pacifier for administering flavour substances
AU2003246143A1 (en) Polypeptide agent for inhibiting sars coronavirus and its derivatives and use thereof
EP1213021A4 (fr) Medicaments contre le diabete

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110808